PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
C07D 471/04, A61K 31/44, C07D 491/04, 495/04, A61P 25/16, 25/24 // (C07D 471/04, 221:00, 209:00) (C07D 491/04, 307:00, 221:00) (C07D 495/04, 333:00, 221:00)

A1

(11) International Publication Number: WO 00/37466

(43) International Publication Date: 29 June 2000 (29.06.00)

(21) International Application Number: PCT/EP99/10054

(22) International Filing Date: 14 December 1999 (14.12.99)

(30) Priority Data:
98204358.0 21 December 1998 (21.12.98) EP

(71) Applicant *(for all designated States except US)*: JANSSEN PHARMACEUTICA N.V. [BE/BE]; Patent Department, Turnhoutseweg 30, B–2340 Beerse (BE).


(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: KENNIS, Ludo, Edmond, Josephine [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE). MERTENS, Josephus, Carolus [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE). PIETERS, Serge, Maria, Aloysius [NL/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE).

(74) Agent: QUAGHEBEUR, Luc; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: BENZISOXAZOLES AND PHENONES AS α_2–ANTAGONISTS



(I)

(57) Abstract

The present invention concerns compounds of formula (I), the *N*–oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Alk is C_{5-12}alkanediyl; n is 1 or 2; p is 1 and q is 2; or p is 2 and q is 1; X is –O–, –S–, –S(=O)–, –S(=O)$_2$– or NR^2; each R^1 is independently hydrogen, halogen, C_{1-6}alkyl, nitro, hydroxy or C_{1-4}alkyloxy; R^2 is hydrogen, C_{1-6}alkyl, aryl or C_{1-6}alkyl substituted with aryl; aryl is phenyl or phenyl substituted with a halogen or C_{1-6}alkyl; D is an optionally substituted benzophenone or 3–benzisoxazolyl; having central α_2–adrenoceptor antagonist activity. It further relates to their preparation, pharmaceutical use and compositions.